依那西普
參考文獻

1 2 3  . Therapeutic Goods Administration (TGA).   [2021-06-12]. （原始内容存档于2021-06-13）.
1 2 3  . European Medicines Agency. 24 March 2020  [2023-03-04]. （原始内容存档于2020-06-04）.
1 2 3  . Therapeutic Goods Administration (TGA).   [2021-06-12]. （原始内容存档于2021-06-13）.
1 2   (PDF). Feb 2021  [2024-01-11]. （原始内容存档 (PDF)于2024-01-14）.
↑  . Drugs.com. 2020-01-24  [2020-08-13]. （原始内容存档于2021-01-20）.
↑  . Health Canada. 2014-10-23  [2023-03-10]. （原始内容存档于2023-05-27）.
1 2 3 4 5 6 7 8 9 10 11 12  . European Medicines Agency (EMA). 2018-09-17  [2020-04-02]. （原始内容存档于2020-11-12）.  Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑  . Union Register of medicinal products.   [2023-03-03]. （原始内容存档于2023-03-05）.
↑  . (emc). 2021-01-25  [2021-06-12]. （原始内容存档于2023-12-28）.
↑  . (emc). 2021 -06-08  [2021-06-12]. （原始内容存档于2023-12-28）.  请检查|date=中的日期值 (帮助)
↑  . (emc). 2021-05-25  [2021-06-12]. （原始内容存档于2024-02-27）.
1 2 3 4 5 6 7 8  . DailyMed.   [2021-04-17]. （原始内容存档于2024-02-28）.
↑  Feldmann M, Maini RN. . Nature Medicine. October 2003, 9 (10): 1245–1250. PMID 14520364. S2CID 52860838. doi:10.1038/nm939.
↑  .   [2024-01-11]. （原始内容存档于2024-04-18）.
↑  Peppel K, Crawford D, Beutler B. . The Journal of Experimental Medicine. December 1991, 174 (6): 1483–1489. PMC 2119031 . PMID 1660525. doi:10.1084/jem.174.6.1483.
↑  Peppel K, Poltorak A, Melhado I, Jirik F, Beutler B. . Journal of Immunology. November 1993, 151 (10): 5699–5703. PMID 7693816. S2CID 10859938. doi:10.4049/jimmunol.151.10.5699.
↑  U.S. Patent number: 5,447,851
↑  .   [2008-01-10]. （原始内容存档于2007-10-20）.
↑  Braun J, McHugh N, Singh A, Wajdula JS, Sato R. . Rheumatology. June 2007, 46 (6): 999–1004. PMID 17389658. doi:10.1093/rheumatology/kem069 .
↑  World Health Organization. . Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
↑   (PDF) (Letter). Letter to Sally Gould. U.S. Food and Drug Administration (FDA). 1998-11-02  [2015-04-14]. （原始内容存档 (PDF)于2015-09-24）.
↑   (PDF) (Letter). Letter to Sally Gould. U.S. Food and Drug Administration (FDA). 1999-05-27  [2015-04-14]. （原始内容存档 (PDF)于2015-09-24）.
↑   (Letter). Letter to Sally Gould. U.S. Food and Drug Administration (FDA). 2002-01-15  [2015-04-14]. （原始内容存档于2021-01-22）.
↑   (PDF) (Letter). Letter to Douglas Hunt. U.S. Food and Drug Administration (FDA). 2003-07-24  [2015-04-14]. （原始内容存档 (PDF)于2021-01-22）.
↑  Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E,  et al. . The Cochrane Database of Systematic Reviews. April 2015, 4 (4): CD005468. PMID 25887212. doi:10.1002/14651858.CD005468.pub2.
↑   (PDF) (Letter). Letter to Douglas Hunt. U.S. Food and Drug Administration (FDA). 2004-04-30  [2015-04-14]. （原始内容存档 (PDF)于2021-01-06）.
↑  . Springer Select. 2012-10-31  [2018-11-17]. （原始内容存档于2021-06-25）.
↑  US 8900583,Tobinick EL,「Methods for treatment of brain injury utilizing biologics」,发表于2014-12-02
↑  . Above the Law. 2017-02-24  [2022-06-27]. （原始内容存档于2023-08-31） （美国英语）.
↑   (pdf). American Academy of Neurology. 2016-06-06  [2024-01-11]. （原始内容存档于2023-01-08）.
↑  .   [2008-05-02]. （原始内容存档于2008-05-05）.
↑   (PDF). U.S. Food and Drug Administration (FDA): 13–14.   [2013-12-20]. （原始内容 (PDF)存档于2015-09-24）.
↑  Kim PJ, Lansang RP, Vender R. . Journal of Cutaneous Medicine and Surgery. July 2023, 27 (4): 358–367. PMC 10486173 . PMID 37533141. doi:10.1177/12034754231188444.
↑  Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C,  et al. . Journal of Immunology. August 2007, 179 (3): 1872–1883. PMID 17641054. doi:10.4049/jimmunol.179.3.1872 .
↑  Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C,  et al. . Journal of Clinical Oncology. September 2005, 23 (25): 5950–5959. PMID 16135466. doi:10.1200/JCO.2005.04.127.
1 2  Smola MG, Soyer HP, Scharnagl E. . European Journal of Surgical Oncology. October 1991, 17 (5): 447–453. PMID 1936291.
↑  Houel S, Hilliard M, Yu YQ, McLoughlin N, Martin SM, Rudd PM,  et al. . Analytical Chemistry. January 2014, 86 (1): 576–584. PMID 24308717. doi:10.1021/ac402726h.
↑  Mukai Y, Nakamura T, Yoshikawa M, Yoshioka Y, Tsunoda S, Nakagawa S,  et al. . Science Signaling. November 2010, 3 (148): ra83. PMID 21081755. S2CID 24226117. doi:10.1126/scisignal.2000954.
↑  Lamanna WC, Mayer RE, Rupprechter A, Fuchs M, Higel F, Fritsch C,  et al. . Scientific Reports. June 2017, 7 (1): 3951. Bibcode:2017NatSR...7.3951L. PMC 5479810 . PMID 28638112. doi:10.1038/s41598-017-04320-5.
↑  Norman P. . Pharmaceutical Patent Analyst. January 2017, 6 (1): 5–7. PMID 28201948. doi:10.4155/ppa-2016-0043.
↑  Gardner J. . 2021-11-01  [2024-01-11]. （原始内容存档于2024-06-03）.
↑  Kowalczyk L. . 2002-03-24  [2024-01-11]. （原始内容存档于2023-10-02）.
↑  . U.S. Food and Drug Administration (FDA). 2016-04-01  [2020-06-04]. （原始内容存档于2017-01-18）.
↑  "What's behind the whopping price tags on the newest generation of drugs: （页面存档备份，存于） The story behind the production of Enbrel, Amgen's popular rheumatoid arthritis drug, provides insights as to why bioengineered drugs are so expensive."  Carol M. Ostrom, Seattle Times, 2008-08-18
1 2 3  Pollock A. . The New York Times. 2011-11-23  [2023-03-10]. （原始内容存档于2021-07-25）.
↑  "Co-pay hike a painful reality; Miracle drug monthly cost jumps from $42 to $600" Archive.is的存檔，存档日期2013-01-18, Margery Eagan, Boston Herald, 2011-11-03
1 2 3 4   (PDF). International Federation of Health Plans.   [2017-11-24]. （原始内容 (PDF)存档于2017-10-22）.
↑  . Sec.gov.   [2019-06-05]. （原始内容存档于2019-06-10）.
↑  .   [2009-12-09]. （原始内容存档于2010-02-24）.
↑  . 2011-11-25  [2019-07-14]. （原始内容存档于2019-07-14）.
↑  Kaldre I. . www.law.duke.edu. 2008  [2019-06-05]. （原始内容存档于2021-08-28）.
↑  Kaldre I. . www.law.duke.edu. 2008  [2019-06-05]. （原始内容存档于2021-08-28）.
↑  . S&P Global Market Intelligence. 2013-04-18  [2023-12-28]. （原始内容存档于2023-12-28）.
↑  . European Medicines Agency (EMA). 2018-09-17  [2020-04-02]. （原始内容存档于2019-12-30）.
↑  . European Medicines Agency (EMA). 2018-09-17  [2 April 2020]. （原始内容存档于2020-11-29）.
↑   (PDF).   [2020-04-02]. （原始内容存档 (PDF)于2021-08-28）.
↑  . European Medicines Agency (EMA). 2018-09-17  [2020-04-02]. （原始内容存档于2019-12-30）.
↑  .   [2024-01-11]. （原始内容存档于2023-12-28）.
↑  . Therapeutic Goods Administration (TGA). 2021-02-25  [2021-06-12]. （原始内容存档于2021-06-13）.